Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
United States Food and Drug Administration Regulation of Clinical Software in the Era of Artificial Intelligence and Machine Learning
16
Zitationen
4
Autoren
2025
Jahr
Abstract
The U.S. Food and Drug Administration (FDA) has been regulating medical devices since 1976. The introduction of novel medical devices including software as a medical device (SaMD) has led to more recent challenges given the rapid evolution of laws, technologies, and review pathways.1 The FDA defines medical devices as an “instrument, apparatus, implement, machine, appliance, implant, reagent for invitro use, software, or material” that can be used in the “diagnosis, cure, mitigation, treatment, and prevention of diseases.”2 This definition excludes medical devices which primarily achieve their intended purpose through pharmacological, immunological, or metabolic means, but devices may be assisted in their function by these means.
Ähnliche Arbeiten
Explainable Artificial Intelligence (XAI): Concepts, taxonomies, opportunities and challenges toward responsible AI
2019 · 8.316 Zit.
Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead
2019 · 8.177 Zit.
High-performance medicine: the convergence of human and artificial intelligence
2018 · 7.575 Zit.
Proceedings of the 19th International Joint Conference on Artificial Intelligence
2005 · 5.776 Zit.
Peeking Inside the Black-Box: A Survey on Explainable Artificial Intelligence (XAI)
2018 · 5.468 Zit.